$14.07
+0.39 (+2.85%)
Last updated: May 31, 2026 07:57
Fundamentals Overview
Intellia Therapeutics, Inc. is in the middle of its 52-week range with premium valuation, trending upward today.
Valuation premium
Risk (Beta)
1.93 — higher vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
3M vs Healthcare sector: +10.1%
Pressures (Sell):
Sentiment weakening (4 downgrades) · Beta 1.93 (elevated)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: C+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 13, Equal Weight: 3, Hold: 1, In Line: 1, Market Outperform: 3, Market Perform: 1, Neutral: 2, Outperform: 1, Overweight: 1, Peer Perform: 1, Sector Perform: 1, Sell: 1, Underweight: 1.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-17.23; current price is $14.07. That’s a -222.5% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | 2.68 |
| P/S (TTM) | 23.89 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 6.1 |
| Quick Ratio (TTM) | 6.1 |
| Cash Ratio (TTM) | 1.76 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -5.97% |
| Gross margin (TTM) | -31.89% |
| Operating margin (TTM) | -6.37% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for NTLA.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Bernstein | maintain | Market Perform | Market Perform | 2026-05-13 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-05-13 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-05-12 |
| Wedbush | maintain | Neutral | Neutral | 2026-05-12 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-04-28 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2026-04-28 |
| Goldman Sachs | maintain | Sell | Sell | 2026-04-28 |
| Citizens | maintain | Market Outperform | Market Outperform | 2026-04-28 |
| Chardan Capital | maintain | Buy | Buy | 2026-04-27 |
| Baird | maintain | Neutral | Neutral | 2026-04-27 |
| Jones Trading | upgrade | Hold | Buy | 2026-03-04 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-03-03 |
| Citizens | maintain | Market Outperform | Market Outperform | 2026-03-03 |
| RBC Capital | maintain | Sector Perform | Sector Perform | 2026-03-03 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2026-03-03 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-03-03 |
| Leerink Partners | maintain | Outperform | Outperform | 2026-03-03 |
| Chardan Capital | maintain | Buy | Buy | 2026-03-02 |
| Chardan Capital | maintain | Buy | Buy | 2026-02-27 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-01-28 |
| Wolfe Research | downgrade | Outperform | Peer Perform | 2025-11-12 |
| Jones Trading | downgrade | Buy | Hold | 2025-11-11 |
| Evercore ISI Group | downgrade | Outperform | In Line | 2025-11-11 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-11-10 |
| Truist Securities | maintain | Buy | Buy | 2025-11-10 |
| Chardan Capital | maintain | Buy | Buy | 2025-11-07 |
| Barclays | maintain | Overweight | Overweight | 2025-11-07 |
| Citizens | maintain | Market Outperform | Market Outperform | 2025-11-07 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2025-11-07 |
| JP Morgan | downgrade | Neutral | Underweight | 2025-11-07 |